Gerald E. Hancock
Praxis
20 Papers
348 Citations
Gerald E. Hancock is an academic researcher from Praxis. The author has contributed to research in topics: Immune system & Virus. The author has an hindex of 11, co-authored 20 publications. Previous affiliations of Gerald E. Hancock include American Cyanamid.
Chat about Author
Papers
Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus.
TL;DR: The results suggest that G, not F, protein has more potential to bias the host for atypical pulmonary inflammatory responses and imply that native G protein influences the nature of the immune responses elicited by F/QS-21.
167
Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection.
Gerald E. Hancock,Dan J. Speelman,Patrick J. Frenchick,Michelle M. Mineo-Kuhn,Raymond B. Baggs,Denise J. Hahn +5 more
TL;DR: In conclusion, the results suggest that formulation with F/QS-21 alters the qualitative and quantitative nature of the immune response to the F glycoprotein when compared with the traditional aluminium-based adjuvants.
93
Effective mucosal immunization against respiratory syncytial virus using purified F protein and a genetically detoxified cholera holotoxin, CT-E29H.
Paul W. Tebbey,Catherine A. Scheuer,Peek Joel A,Duzhang Zhu,Natisha A. LaPierre,Bruce A. Green,Eric D Phillips,Alexander R Ibraghimov,John H. Eldridge,Gerald E. Hancock +9 more
TL;DR: The results demonstrated that CT-E29H binding to GM1 ganglioside was equivalent, ADP-ribosylation of agmatine was 11.7%, and toxicity was attenuated in both Y-1 adrenal and patent mouse gut weight assays have important implications for vaccine strategies that use genetically detoxified mutant cholera holotoxins for the mucosal delivery of highly purified RSV antigens.
54
CpG containing oligodeoxynucleotides are potent adjuvants for parenteral vaccination with the fusion (F) protein of respiratory syncytial virus (RSV).
Gerald E. Hancock,Kristen M. Heers,Jason D. Smith,Catherine A. Scheuer,Alexander R Ibraghimov,Karin S. Pryharski +5 more
TL;DR: The results suggest a novel formulation for naïve recipients of F protein-based subunit vaccines that does not result in a type 2 phenotype, and the statistically significant increases in serum IFNgamma and anti-F protein IgG2a titers indicated that CpG ODN enhanced the ability of F/AlOH to elicit type 1 immune responses.
52
Adjuvants recognized by toll-like receptors inhibit the induction of polarized type 2 T cell responses by natural attachment (G) protein of respiratory syncytial virus.
TL;DR: It is demonstrated using BALB/c mice that enhanced neutralization titers and accelerated clearance of virus from the lungs after challenge are possible if the attachment (G) glycoprotein is added to F protein-based vaccines.
50